The latest news from academia, regulators
research labs and other things of interest
Posted: October 15, 2007
Acrongenomics Successfully Demonstrates Creatinine Measurement in Urine on Standalone Demonstrator Device
(Nanowerk News) Acrongenomics, Inc. (OTCBB:AGNM) and its research partner Molecular Vision Ltd. are pleased to announce the successful implementation of a fully functional, portable medical diagnostic demonstrator of their Lab-on-a-Chip technology. The demonstrator employs patented, organic semiconductor technology in a high sensitivity, handheld, medical diagnostic device. The successful presentation of the demonstrator device took place at Imperial College in London, UK, on October 11th 2007.
The technology uses semiconductor films located on either side of a microfluidics chip. One film illuminates the chip, where appropriate, while the other film detects an output signal, which is fed to a display. The demonstrated device can be implemented into three forms of detection utilizing absorbance, chemiluminescence and fluorescence to detect different markers of interest.
The standalone two-channel, battery-powered device, complete with digital display and self-referencing capability has demonstrated its capability to measure clinically relevant markers with high sensitivity and at low cost. In particular, the demonstrator device has been used successfully to measure creatinine in urine at physiologically significant concentrations. The results, obtained within seconds, were comparable to those obtained using a bench top spectrometer.
The portable nature of the technology, in combination with the digital read-out shows the potential use of the technology as a near patient testing platform. Dr. Dimitris Goundis, CEO of Acrongenomics commented, “The ability to measure a protein in-situ repeatedly and accurately, in this case creatinine in urine, is a monumental achievement for our technology and clearly demonstrates its numerous capabilities.“
Acrongenomics & Molecular Vision believe that this technology is capable of further miniaturization along with large scale, low cost manufacturing, which will significantly enhance disposable, Point-of-Care diagnostics for kidney and cardiac biomarkers.
About Acrongenomics Inc.
Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications. The company has its headquarters in Geneva, Switzerland.
About Molecular Vision Ltd
Molecular Vision is a spin-out company of Imperial Innovations Ltd. The company was founded by three Imperial College London researchers -- Prof. Donal Bradley, Prof. Andrew de Mello and Dr. John de Mello -- in 2002 in order to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets: the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets. Molecular Vision recently signed a major development contract with Acrongenomics Inc. to jointly exploit and commercialize the technology.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions. For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.